Diagnosis of Lupus Anticoagulants

  • D. A. Triplett
Conference paper


Antiphospholipid antibodies (APA) are a family of immunoglobulins which habe been defined by in vitro laboratory tests [1,2]. The immunoglobulin may be of IgG, IgM, or IgA isotypes. In the majority of patients, they are polyclonal although occasionally monoclonal APAs are identified in patients with hematologic malignancies [3]. Often, within an individual patient, there may be a mixture of isotypes with differing reactivity toward negatively charged phospholipids. Recent observations would suggest that this group of antibodies may, in fact, be misnamed. There is increasing evidence that the antigenic target(s) may be a complex(es) of phospholipid and protein(s) [4, 5]. For example, anticardiolipin antibodies (ACA) require the presence of a plasma protein, beta2 glycoprotein I (apolipoprotein H) for optimal reactivity in a solid phase ELISA assay [6,7].


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Triplett DA, Brandt JT (1988) Lupus anticoagulants: misnomer, paradox, riddle, epiphenomenon. Hematol Pathol 2: 121–143PubMedGoogle Scholar
  2. 2.
    Love PE, Santoro SA (1990) Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Ann Intern Med 112: 682–698PubMedGoogle Scholar
  3. 3.
    Thiagarajan P, Shapiro SS, DeMarco L (1980) Monoclonal immunoglobulin MA coagulation inhibitor with phospholipid specificity: mechanism of a lupus anticoagulant. J Clin Invest 66: 397–405PubMedCrossRefGoogle Scholar
  4. 4.
    Galli M, Comfurius P, Maassen C, Hemker HC, de Baets MH, van Breda-Vriesman PJC, Barbui T, Zwaal RFA, Bevers EM (1990) Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma cofactor. Lancet 335: 1544–1547PubMedCrossRefGoogle Scholar
  5. 5.
    McNeil HP, Simpson RJ, Chesterman CN, Krilis SA (1990) Antiphospholipid antibodies are directed against a complex antigen that includes a lipid binding inhibitor of coagulation: ß2 glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 87: 4120–4124PubMedCrossRefGoogle Scholar
  6. 6.
    Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Koike T (1990) Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 336: 177–178PubMedCrossRefGoogle Scholar
  7. 7.
    Galli M, Comfurius P, Barbui T, Zwaal RFA, Bevers EM (1992) Anticoagulant activity of ß2 glycoprotein I is potentiated by a distinct subgroup of anticardiolipin antibodies. Thromb Haemost 68: 297–300PubMedGoogle Scholar
  8. 8.
    Triplett DA, Brandt JT, Maas RL (1985) The laboratory heterogeneity of lupus anticoagulants. Arch Pathol Lab Med 109: 946–951PubMedGoogle Scholar
  9. 9.
    Mannucci PM, Canciani MT, Mari D, Meucci P (1979) The varied sensitivity of partial thromboplastin and prothrombin time reagents in the demonstration of lupus-like anti-coagulant. Scand J Haematol 22: 423–432PubMedCrossRefGoogle Scholar
  10. 10.
    Bevers EM, Galli M, Barbui T, Comfurius P, Zwaal RFA (1991) Lupus anticoagulant IgG’s (LA) are not directed to phospholipids only but to a complex of lipid bound prothrombin. Thromb Haemost 66: 629–632PubMedGoogle Scholar
  11. 11.
    Potzsch B, Kawamura H, Preissner T, Seelig C, Muller-Berghaus G (1993) Thrombophilia in patients with lupus anticoagulant correlates with impaired anticoagulant activity of activated protein C but not with reduced thrombomodulin activity. Thromb Haemost 69: 542 (abstract 12)Google Scholar
  12. 12.
    Janoff AS, Rauch J (1986) The structural specificity of antiphospholipid antibodies in autoimmune disease. Chem Phys Lipids 40: 315–332PubMedCrossRefGoogle Scholar
  13. 13.
    Rauch J, Janoff AS (1990) Phospholipid in the hexagonal II phase is immunogenic. Evidence for immuno recognition of nonbilayer lipid phases in vivo. Proc Natl Acad Sci USA 87: 4112–4114PubMedCrossRefGoogle Scholar
  14. 14.
    Conley CL, Hartmann RC (1952) A hemorrhagic disorder caused by circulating anticoagulants in patients with disseminated lupus erythematosus. J Clin Invest 31: 621–622Google Scholar
  15. 15.
    McNeil HP, Chesterman CN, Krilis SA (1991) Immunology and clinical importance of antiphospholipid antibodies. Adv Immunol 49: 193–280PubMedCrossRefGoogle Scholar
  16. 16.
    Triplett DA (1989) Antiphospholipid antibodies and recurrent pregnancy loss. Am J Reprod Immunol 20: 52–67PubMedGoogle Scholar
  17. 17.
    Triplett DA (1989) Screening for the lupus anticoagulant. Res Clin Lab 19: 379–389Google Scholar
  18. 18.
    Triplett DA (1992) Coagulation assays for the lupus anticoagulant: review and critique of current methodology: Stroke 23 [Suppl I]: 111–114Google Scholar
  19. 19.
    Triplett DA, Brandt JT, Musgrave KA, Orr CA (1988) The relationship between lupus anticoagulants and antibodies to phospholipid. JAMA 259: 550–554PubMedCrossRefGoogle Scholar
  20. 20.
    Green D, Hougie C, Kazmier FJ et al (1983) Report of the working party on acquired inhibitors of coagulation: studies of the “lupus anticoagulant.” Thromb Haemost 49: 144–146PubMedGoogle Scholar
  21. 21.
    Exner T, Triplett DA, Taberner D, Machin S J (1991) Guidelines for testing and revised criteria for lupus anticoagulants. SSC Subcommittee for the Standardization of Lupus Anticoagulants. Thromb Haemost 65: 320–322PubMedGoogle Scholar
  22. 22.
    Exner T (1985) Comparison of two simple tests for the lupus anticoagulant. Am J Clin Pathol 82: 215–218Google Scholar
  23. 23.
    Kelsey PR, Stevenson KJ, Poller L (1984) The diagnosis of lupus anticoagulants by the activated partial thromboplastin time - the central role of phosphatidylserine. Thromb Haemost 52: 172–175PubMedGoogle Scholar
  24. 24.
    Exner T, Rickard KA, Kronenberg H (1978) A sensitive test demonstrating lupus anticoagulant and its behavioral pattern. Br J Haematol 40: 143–151PubMedCrossRefGoogle Scholar
  25. 25.
    Thiagarajan P, Pengo V, Shapiro SS (1986) The use of the dilute Russell viper venom time for the diagnosis of lupus anticoagulants. Blood 68: 869–874PubMedGoogle Scholar
  26. 26.
    Gibson J, Starling E, Date L, Rickard KA, Kronenberg H (1988) Simplified screening procedures for detecting lupus inhibitor. J Clin Pathol 41: 226–231PubMedCrossRefGoogle Scholar
  27. 27.
    Brandt JT, Triplett DA (1989) The effect of phospholipid on the detection of lupus anti-coagulants by the dilute Russell viper venom time. Arch Pathol Lab Med 113: 1376–1378PubMedGoogle Scholar
  28. 28.
    Exner T, Sochynsky CL (1993) Evaluation of the DVVtest/DVV confirm system for diagnosis of lupus anticoagulants. Thromb Haemost 69: 1034 (abstract 1746)Google Scholar
  29. 29.
    Triplett DA, Stocker KF, Unger GA, Barna LK (1993) The textarin-ecarin ratio: a confirmatory test for lupus anticoagulants. Thromb Haemost 70: 925–931PubMedGoogle Scholar
  30. 30.
    Mackie I J, Rooney AM, McNally T, Machin SJ (1993) The taipan snake venom time. Blood 82 [Suppl I]: 408a (abstract 1618)Google Scholar
  31. 31.
    Kaczor DA, Bickford NM, Triplett DA (1991) Evaluation of different mixing study reagents and dilution effect in lupus anticoagulant testing. Am J Clin Pathol 95: 408–411PubMedGoogle Scholar
  32. 32.
    Clyne LP, White PF (1988) Time dependency of lupus-like anticoagulants. Arch Int Med 48: 1060–1063CrossRefGoogle Scholar
  33. 33.
    Schleider MA, Nachman RL, Jaffe EA, Coleman M (1976) A clinical study of the lupus anticoagulant. Blood 48: 499–509PubMedGoogle Scholar
  34. 34.
    Alving BM, Barr CF, Johansen LE, Tang DB (1992) Comparison between a one-point dilute phospholipid APTT and the dilute Russell viper venom time for varification of lupus anticoagulants. Thromb Haemost 67: 672–678PubMedGoogle Scholar
  35. 35.
    Triplett DA, Brandt JT, Kaczor D, Scaeffer J (1983) Laboratory diagnosis of lupus inhibitors: a comparison of the tissue thromboplastin inhibition procedure with a new platelet neutralization procedure. Am J Clin Pathol 79: 678–682PubMedGoogle Scholar
  36. 36.
    Duncan A, Mullins RE, Maxwell LM (1993) A novel phospholipid reagent for use in the platelet neutralization procedure test. Thromb Haemost 69: 1032 (abstract 1741)Google Scholar
  37. 37.
    Rauch J, Tannenbaum M, Janoff AS (1989) Distinguishing plasma lupus anticoagulants from anti-factor antibodies using hexagonal (II) phase phospholipids. Thromb Haemost 62: 892–896PubMedGoogle Scholar
  38. 38.
    Triplett DA, Barna LK, Unger GA (1993) A hexagonal (II) phase phospholipid neutralization assay for lupus anticoagulant identification. Thromb Haemost 70: 787–793PubMedGoogle Scholar
  39. 39.
    Harris EN, Gharavi AE, Boey ML et al (1983) Anticardiolipin antibodies - detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 11: 1211–1214CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1994

Authors and Affiliations

  • D. A. Triplett

There are no affiliations available

Personalised recommendations